MedCost Clear Cost calculator

Drugs / Keytruda

Keytruda cost

pembrolizumab · Merck. Every official price for Keytruda, side by side, with who pays it.

Short answer

Merck lists Keytruda at $12,517.44 per dose given every 3 weeks ($25,034.88 for a dose given every 6 weeks), as of September 2026. Medicare Part B pays up to $62.253 per mg for Keytruda, IV and $32.307 per mg for Keytruda Qlex, under the skin (October 1, 2026 to December 31, 2026). In 2024, Medicare Part B spent $6.0 billion on Keytruda (HCPCS J9271), an average of $13,136.81 per claim (CMS).126

Source: Merck and CMS · checked Nov 15, 2026

Keytruda: the official numbers, by situation

PriceAmountWhose price, and who it applies toDate
List price
per dose given every 3 weeks ($25,034.88 for a dose given every 6 weeks)
$12,517.441 Merck's price to wholesalers (WAC). Most people don't pay it directly. September 2026
Medicare Part B payment limit
per mg, Keytruda, IV
$62.2532 What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026
Medicare Part B payment limit
per mg, Keytruda Qlex, under the skin
$32.3072 What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026

None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.

FDA approval

Every official price

PriceAmountWhat it isDate
Maker's list price (WAC) $12,517.441 Per dose given every 3 weeks ($25,034.88 for a dose given every 6 weeks). The price the maker charges wholesalers; most people do not pay it directly. September 2026 (checked Oct 22, 2026)
Medicare Part B payment limit
Keytruda, IV (pembrolizumab) · HCPCS J9271
$62.2532 Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026
Medicare Part B payment limit
Keytruda Qlex, under the skin (pembrolizumab and berahyaluronidase alfa) · HCPCS J9277
$32.3072 Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026
Pharmacy acquisition cost (NADAC)Not listedThis drug is not in the NADAC survey, which covers drugs dispensed by retail pharmacies.—

These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.3

What Medicare spent on Keytruda in 2024

CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,7 and it does not reflect manufacturers' rebates.8

Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).

Product (as CMS lists it)Total spendingFillsPeoplePer fillPer person
Keytruda $140.1 million5 11,882 1,906 $11,787.1610 $73,481.1311

For doses given in a clinic and paid under Part B, CMS's spending is the full value of the drug, including the Medicare payment and what the patient owed.9

Medicare Part B, calendar year 2024 (CMS Medicare Part B Spending by Drug, checked Nov 15, 2026).

HCPCS codeTotal spendingClaimsPeoplePer claimPer person
J9271
Injection, pembrolizumab, 1 mg
$6.0 billion6 455,858 75,361 $13,136.81 $79,464.46

These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.

With Medicare

With commercial insurance or no insurance

Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.

Official sources for this page (11)
  1. “The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $25,034.88. The list price is current as of September 2026.”
  2. “The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
  3. “BLA125514 ORIG-1 approved 20140904”
  4. “Keytruda: Tot_Spndng_2024 140055039.83, Tot_Clms_2024 11882, Tot_Benes_2024 1906”
  5. “J9271 Injection, pembrolizumab, 1 mg: Tot_Spndng_2024 5988521233, Tot_Clms_2024 455858, Tot_Benes_2024 75361”
  6. “Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
  7. “The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
  8. “Drug spending metrics for Part B drugs represent the full value of the product, including the Medicare payment and beneficiary liability.”
  9. “Part D drug spending divided by the number of prescription fills.”
  10. “Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”

Did this page answer your question?